CY1120269T1 - Ετεροδικυκλικες ενωσεις ως αναστολεις βητα-λακταμασης - Google Patents

Ετεροδικυκλικες ενωσεις ως αναστολεις βητα-λακταμασης

Info

Publication number
CY1120269T1
CY1120269T1 CY20181100311T CY181100311T CY1120269T1 CY 1120269 T1 CY1120269 T1 CY 1120269T1 CY 20181100311 T CY20181100311 T CY 20181100311T CY 181100311 T CY181100311 T CY 181100311T CY 1120269 T1 CY1120269 T1 CY 1120269T1
Authority
CY
Cyprus
Prior art keywords
beta
heterocyclic compounds
compounds
lactam inhibitors
pharmaceutically acceptable
Prior art date
Application number
CY20181100311T
Other languages
English (en)
Inventor
Helen Mcguire
Shanta Bist
Neil Bifulco
Ye Wu
Hoan Huynh
Hui Xiong
Janelle Comita-Prevoir
Daemian DUSSAULT
Bolin Geng
Brendan CHEN
Thomas Durand-Reville
Satenig GULER
Liang Zhao
Original Assignee
Entasis Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Limited filed Critical Entasis Therapeutics Limited
Publication of CY1120269T1 publication Critical patent/CY1120269T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση προσανατολίζεται σε ενώσεις που είναι αναστολείς βητα-λακταμάσης. Οι ενώσεις και τα φαρμακευτικά αποδεκτά άλατα τους είναι χρήσιμα σε συνδυασμό με αντιβιοτικά βητα-λακτάμης ή από μόνα τους, για την αγωγή βακτηριακών λοιμώξεων, συμπεριλαμβανομένων λοιμώξεων που προκαλούνται από ανθεκτικούς οργανισμούς, συμπεριλαμβανομένων πολυανθεκτικών οργανισμών. Η παρούσα εφεύρεση περιλαμβάνει ενώσεις σύμφωνα με τον τύπο (la) ή ένα φαρμακευτικά αποδεκτό άλας αυτής, όπου οι τιμές των R1, R2, R3 και R4 περιγράφονται στο παρόν.
CY20181100311T 2012-04-02 2018-03-14 Ετεροδικυκλικες ενωσεις ως αναστολεις βητα-λακταμασης CY1120269T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618993P 2012-04-02 2012-04-02
PCT/GB2013/050869 WO2013150296A1 (en) 2012-04-02 2013-04-02 Heterobicyclic compounds as beta-lactamase inhibitors

Publications (1)

Publication Number Publication Date
CY1120269T1 true CY1120269T1 (el) 2019-07-10

Family

ID=48083562

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100311T CY1120269T1 (el) 2012-04-02 2018-03-14 Ετεροδικυκλικες ενωσεις ως αναστολεις βητα-λακταμασης

Country Status (41)

Country Link
US (2) US9309245B2 (el)
EP (1) EP2834239B1 (el)
JP (1) JP6122484B2 (el)
KR (1) KR102042867B1 (el)
CN (1) CN104364254B (el)
AP (1) AP2014007980A0 (el)
AR (1) AR090539A1 (el)
AU (1) AU2013245399B2 (el)
BR (1) BR112014024279B1 (el)
CA (1) CA2866467C (el)
CL (1) CL2014002589A1 (el)
CO (1) CO7071137A2 (el)
CR (1) CR20140428A (el)
CY (1) CY1120269T1 (el)
DK (1) DK2834239T3 (el)
DO (1) DOP2014000212A (el)
ES (1) ES2663416T3 (el)
HK (1) HK1207071A1 (el)
HR (1) HRP20180450T1 (el)
HU (1) HUE036722T2 (el)
IL (1) IL234660A (el)
IN (1) IN2014MN01882A (el)
LT (1) LT2834239T (el)
MA (1) MA37383A1 (el)
ME (1) ME03031B (el)
MX (1) MX354627B (el)
MY (1) MY176969A (el)
NO (1) NO2935238T3 (el)
NZ (1) NZ630259A (el)
PE (1) PE20142403A1 (el)
PH (1) PH12014502224A1 (el)
PL (1) PL2834239T3 (el)
PT (1) PT2834239T (el)
RS (1) RS56966B1 (el)
RU (1) RU2645678C2 (el)
SG (1) SG11201405965RA (el)
SI (1) SI2834239T1 (el)
TN (1) TN2014000417A1 (el)
TW (1) TWI597281B (el)
UY (1) UY34723A (el)
WO (1) WO2013150296A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
KR102542392B1 (ko) * 2014-11-17 2023-06-09 엔타시스 테라퓨틱스 리미티드 내성 박테리아 감염의 치료를 위한 배합물 치료제
BR112017020826A2 (pt) 2015-03-31 2018-07-03 Mutabilis compostos, composição farmacêutica e kit
EP3075733A1 (en) * 2015-03-31 2016-10-05 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
CA2980085A1 (en) * 2015-03-31 2016-10-06 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
EP3075381A1 (en) * 2015-04-03 2016-10-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
TW201639854A (zh) * 2015-04-03 2016-11-16 木塔比利斯公司 雜環化合物及其用於預防或治療細菌感染的用途
CA2983674A1 (en) * 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3091018A1 (en) * 2015-05-07 2016-11-09 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US9951072B2 (en) 2015-10-02 2018-04-24 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
EP3184529A1 (en) * 2015-12-23 2017-06-28 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017203266A1 (en) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
KR102667828B1 (ko) * 2016-09-16 2024-05-20 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3300736B1 (en) 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
MX2019013291A (es) * 2017-05-08 2020-01-15 Entasis Therapeutics Inc Compuestos y metodos para tratar infecciones bacterianas.
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11497731B2 (en) 2018-05-14 2022-11-15 National University Corporation Tokai National Higher Education And Research System β-lactamase inhibitor
EP3608318A1 (en) * 2018-08-09 2020-02-12 Antabio SAS Diaazabicyclooctanone derivatives as antibacterials
RS64679B1 (sr) * 2018-08-09 2023-11-30 Antabio Sas Diazabiciklooktanoni kao inhibitori serinskih beta-laktamaza
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
RU2739761C2 (ru) * 2018-09-27 2020-12-28 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения n-алкил-n-{ [3-алкил-3,8-диазабицикло[3.2.1]окта-1(7),5-диен-8-ил]метил} аминов и их применение в качестве средств с антимикробной активностью
CN111196808B (zh) * 2018-11-16 2022-10-18 南京圣和药业股份有限公司 二氮杂双环类化合物及其应用
CN110615790A (zh) * 2019-10-24 2019-12-27 北京融英医药科技有限公司 一种利格列汀制备工艺的改进方法
US20220194791A1 (en) * 2020-12-22 2022-06-23 Tokyo Ohka Kogyo Co., Ltd. Method for producing aqueous solution of purified orthoperiodic acid, method for producing semiconductor device, and aqueous solution of orthoperiodic acid
CN113979981B (zh) * 2021-10-22 2023-04-07 天津医科大学 一种巯基响应型脱碱基位点捕获试剂及应用
WO2023206580A1 (en) 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms
CN118271319A (zh) * 2022-12-30 2024-07-02 成都四面体药物研究有限公司 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
CN116693531A (zh) * 2023-06-09 2023-09-05 河南师范大学 一种桥联多环内酰胺类化合物的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699465B2 (en) * 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
ES2433744T3 (es) * 2008-01-18 2013-12-12 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasas
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2135959A1 (en) * 2008-06-19 2009-12-23 Novexel Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
PT2748165T (pt) 2011-08-27 2016-12-28 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas
EP2872510B1 (en) 2011-08-30 2016-11-23 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
RU2014143821A (ru) 2012-03-30 2016-05-27 Кьюбист Фармасьютикалз, Инк. 1, 3, 4-ОКСАДИАЗОЛЬНЫЕ И 1, 3, 4-ТИАДИАЗОЛЬНЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗЫ
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
PL2857401T3 (pl) 2012-05-30 2020-02-28 Meiji Seika Pharma Co., Ltd. NOWY INHIBITOR ß–LAKTAMAZY I SPOSÓB JEGO WYTWARZANIA
BR112015003592B1 (pt) 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Also Published As

Publication number Publication date
US20150073011A1 (en) 2015-03-12
US20160175290A1 (en) 2016-06-23
CR20140428A (es) 2015-01-12
PE20142403A1 (es) 2015-01-23
ES2663416T3 (es) 2018-04-12
CL2014002589A1 (es) 2015-01-30
NO2935238T3 (el) 2018-05-26
DOP2014000212A (es) 2014-10-31
SG11201405965RA (en) 2014-10-30
CO7071137A2 (es) 2014-09-30
IL234660A (en) 2017-08-31
TW201345907A (zh) 2013-11-16
PH12014502224B1 (en) 2015-01-12
AR090539A1 (es) 2014-11-19
TWI597281B (zh) 2017-09-01
HRP20180450T1 (hr) 2018-06-01
EP2834239B1 (en) 2017-12-27
MX354627B (es) 2018-03-14
MY176969A (en) 2020-08-28
JP6122484B2 (ja) 2017-04-26
PT2834239T (pt) 2018-03-23
BR112014024279A8 (pt) 2018-04-03
AU2013245399A1 (en) 2014-10-02
NZ630259A (en) 2016-06-24
PL2834239T3 (pl) 2018-06-29
CN104364254B (zh) 2017-02-22
RU2645678C2 (ru) 2018-02-27
WO2013150296A1 (en) 2013-10-10
MX2014011351A (es) 2014-12-05
UY34723A (es) 2015-07-31
PH12014502224A1 (en) 2015-01-12
KR102042867B1 (ko) 2019-11-08
RU2014141579A (ru) 2016-05-27
BR112014024279B1 (pt) 2021-09-08
LT2834239T (lt) 2018-03-26
TN2014000417A1 (en) 2016-03-30
IN2014MN01882A (el) 2015-07-10
CA2866467C (en) 2020-03-24
HK1207071A1 (en) 2016-01-22
CA2866467A1 (en) 2013-10-10
AP2014007980A0 (en) 2014-10-31
HUE036722T2 (hu) 2018-07-30
ME03031B (me) 2018-10-20
EP2834239A1 (en) 2015-02-11
DK2834239T3 (en) 2018-03-26
RS56966B1 (sr) 2018-05-31
KR20140140625A (ko) 2014-12-09
BR112014024279A2 (el) 2017-06-20
SI2834239T1 (en) 2018-05-31
US9309245B2 (en) 2016-04-12
CN104364254A (zh) 2015-02-18
JP2015512440A (ja) 2015-04-27
MA37383A1 (fr) 2016-06-30
US9623014B2 (en) 2017-04-18
AU2013245399B2 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
CY1120269T1 (el) Ετεροδικυκλικες ενωσεις ως αναστολεις βητα-λακταμασης
CY1124086T1 (el) Παραγωγα 3-τετραζολυλ-βενζεν-1,2-δισουλφοναμιδιου ως αναστολεις μεταλλο-βητα-λακταμασης
CY1117955T1 (el) Αμιδινο-υποκατεστημενες ενωσεις βητα-λακταμης, παρασκευη και χρηση τους ως αντιβακτηριακοι παραγοντες
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CY1120104T1 (el) Αναστολεις της syk
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
PH12019500558A1 (en) Beta-lactamase inhibitor compounds
CY1118656T1 (el) Παραγωγο πυριδονης
CY1117905T1 (el) Αναστολεις πρωτεϊνικης κινασης
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1123705T1 (el) Αλατα και πολυμορφα μιας ενωσης τετρακυκλινης
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CY1120127T1 (el) Παραγωγο πυριδινης
CY1119842T1 (el) Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv
CY1118610T1 (el) Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου
CY1121384T1 (el) Συνδυαστικη θεραπεια για την αγωγη ανθεκτικων βακτηριακων λοιμωξεων
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
EA201290632A1 (ru) Производные бетулина
CY1119289T1 (el) Παραγωγα 1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης υποκατεστημενα με ετεροκυκλικους δακτυλιους ως αντι-ιικοι παραγοντες αναπνευστικου συγκυτιακου ιου
CY1120355T1 (el) Αναστολεις toy iap
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
CY1119425T1 (el) Ενωσεις φαινοξυαιθυλο πιπεριδινης
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
MX2015017156A (es) Inhibidores de bace.